Interventions of Interest
For questions please contact [email protected].
- ifezuntrigene inilparvovec (uniQure N.V. )
Huntington’s Disease
An assessment of ifezuntrigene inilparvovec
Public Meeting
March 2027
Assessment Status
Ongoing
Upcoming Milestone
Draft Scoping DocumentView
Main Review
March 25, 2027
Midwest CEPAC
The Midwest CEPAC 2027 public meeting on ifezuntrigene inilparvovec for Huntington’s Disease.
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- HD-CARE
- HD Reach
- Help for HD International
- Huntington’s Disease Society of America
- Huntington’s Disease Youth Organization (HDYO)
- uniQure N.V.
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Public Comment Period
See Full Timeline
08/20/2026 - 09/11/2026
Public Comments on Draft Scoping Document
Related Assessments & Policy Papers.
08/20/2026 - 09/11/2026
Public Comments on Draft Scoping Document
09/21/2026
Revised Scoping Document
09/29/2026
Research Protocol
Please find the Research Protocol here:
11/16/2026
Model Analysis Plan
Please find the model analysis plan here:
03/09/2027
Evidence Report
03/25/2027
Evidence Presentation
04/29/2027
Public Comments
OpenView
Closed